Pharma/PBMs

New research on GLP-1s point to a clear need for more sustainable models—ones that pair access with clinical oversight, behavior change and cost management strategies.

Employee demand for GLP-1s continues to surge as prices are primed to start lowering, prompting many orgs to rethink plan design to balance employee expectations and costs.

Experts say this PBM request for proposal season could be among the most consequential employers have ever faced.

The latest polling from KFF shows that about four in 10 U.S. adults (41%) say it is likely the Trump administration's policies will lower prescription drug costs for people like them, but views generally follow party lines.

Consumer health advertising is driving many employees to take action on GLP-1s. But without guidance, those decisions could be risky, new research finds.

Households that earn the median annual income would need to spend an average of 7.3% of their earnings to pay for 2 mg of Ozempic.